Skip to main content

MorphoSys Value Stock - Dividend - Research Selection


ISIN: DE0006632003, WKN: 663200

Market price date: 17.05.2022
Market price: 18,50 EUR

MorphoSys Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 27-03-2022
Cash flow
Net operating cash flow -481.445.000
Capital Expenditures -3.810.210
Free cash flow -485.255.200
Balance sheet
Total Equity 244.876.000
Liabilities & Shareholders equity 2.556.250.000
Income statement
Net income -514.460.000
Eps (diluted) -15,400
Diluted shares outstanding 34.148.800
Net sales/revenue 179.612.000

Fundamental ratios calculated on: 17-05-2022

Key figures 17-05-2022
Cash flow
P/C -1,31
P/FC -1,30
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization766.225.344,00 USD
IndicesCDAX,HDAX,Prime All Share,SDAX,TecDAX
Raw Data SourceIFRS in Millionen EUR
Stock Split2008-12-23,3.0000/1.0000

Description of the company

Morphosys AG is a German biotechnology company focused on generation of fully human antibodies. It operates two business segments: Partnered Discovery and Proprietary Development. The Partnered Discovery business segment comprises technologies for the generation of human antibody therapeutics, which is exploited via partnerships with multiple pharmaceutical and biotechnology companies. The Proprietary Development business segment involves all activities relating to proprietary therapeutic antibody development, primarily including three main compounds in the Company's proprietary product portfolio, MOR103, MOR202 and MOR208, as well as five programs in the discovery phase and two pre-development programs with Novartis. On January 10, 2013, it announced the completion of the divestment of the AbD Serotec segment, which was engaged in the design and manufacture of antibodies for research and diagnostic purposes, including the Human Combinatorial Antibody Library ( HuCAL) technology

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,